Dr. Frances Shepherd CV - (NCRI) is

45. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P; International Staging
Committee including Shepherd FA, and Participating Institutions. The impact of
additional prognostic factors on survival and their relationship with the anatomical extent
of disease expressed by the 6 th edition of the TNM Classification of Malignant Tumors
and the proposals for the 7 th edition. J Thorac Oncol. 2008 May; 3:457-66.
46. Zhu CQ, da cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P,
Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS, National
Cancer Institute of Canada Clinical Trials Group Study BR.21. Role of KRAS and EGFR
as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical
trials Group Study BR.21. J Clin Oncol. 2008 Sep 10: 26:4268-75.
47. Fruh M, Rolland E, Pignon JP, Seymour L, Ding K, Tribodet H, Winton T, le Chevalier
T, Scaliotti GV, Douillard JY, Spiro S, Shepherd FA. Pooled analysis of the effect of
age on adjuvant cisplatin-based chemotherapy for completely resected non-small cell
lung cancer. J Clin Oncol. 2008; 26: 3573-81
48. Director’s Challenge Consortium for the Molecular Classification of Lung
Adenocarcinoma, Shedden K, Taylor JM, Enkemann SA, Tsao MS, Jurisica I, Zhu CQ,
Strumpf D, Shepherd FA, Ding K, Seymour L, Rusch K, Meyerson M, Dobbin KK,
Lively T, Jacobson JW, Beer DG. Gene expression-based survival prediction in lung
adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008 Aug: 14: 822-7.
49. Bezjak A, Lee CW, Ding K, Brundage M, Winton T, Graham B, Whitehead M, Johnson
DH, Livingston RB, Seymour L, Shepherd FA. Quality-of-life outcomes for adjuvant
chemotherapy in early-stage non-small cell lung cancer. J Clin Oncol. 2008 Nov 1; 26:
5052-9.
50. Wheatley-Price P, Shepherd FA. Targeting angiogenesis in the treatment of lung cancer.
J Thorac Oncol. 2008; 3: 1173-84.
51. Travis WD, Giroux DJ, Chansky K, Crowley J, Asamura H, Brambilla E, Jett J, Kennedy
C, Rami-Porta R, Rusch VW, Goldstraw P, International Staging Committee including
Shepherd FA and Participating Institutions. The IASLC Staging Project: poposals for the
inclusion of broncho-pulmonary carcinoid tumors in forthcoming (seventh) edition of the
TNM Classification for Lung Cancer. J Thorac Oncol. 2008 Nov; 3: 1213-23.
52. McKay JD, Hung RJ, Gaborieau V, Shepherd FA, Field J, Lathrop M, Brennan P. Lung
cancer susceptibility locus at 5p15.33. Nat Genet. 2008 Dec: 40: 1404-6.
53. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers,
Shepherd FA, Lippman SM, Douillard JY et al. Gefitinib versus docetaxel in previously
treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet. 2008;
372:1809-18.
54. Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, Leighl NB, Shepherd FA,
Powers J, Seymour L, Laurie SA. Tumor cavitation; impact on objective response evaluation
in trials of angiogenesis inhibitors in non-small cell lung cancer. J Clin Oncol. 2009; 27: 404-
10.
55. Goss G, Shepherd FA, Laurie S, Gauthier I, Leighl N, Chen E, Feld R, Powers J, Seymour L.
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular
endothelial growth factor tyrosine kinases, in combomation with cisplatin and gemcitabine in
patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of
Canada Clinical Trials Group. Eur J Cancer. 2009; 45: 782-8
56. Ellis J, Lin J, Walsh A, Lo C, Shepherd FA, Moore M, Li M, Gagliese L, Zimmerman C,
Rodin G. Predictors of referral for specialized psychosocial oncology care in patients with
metastatic cancer; the contributions of age, distress, and marital status. J Clin Oncol. 2009 Feb
10; 27: 699-705..
57. Al Husaini H, Wheatley-Price P, Clemons M, Shepherd FA. Prevention and management of
bone metastases in lung cancer: a review. J Thorac Oncol. 2009 Feb; 4: 251-9.
9